Your browser is no longer supported. Please, upgrade your browser.
Settings
JNJ Johnson & Johnson daily Stock Chart
JNJ [NYSE]
Johnson & Johnson
IndexDJIA S&P500 P/E20.01 EPS (ttm)5.71 Insider Own0.02% Shs Outstand2.72B Perf Week-0.41%
Market Cap310.68B Forward P/E16.04 EPS next Y7.12 Insider Trans-8.11% Shs Float2.71B Perf Month-1.61%
Income15.94B PEG3.07 EPS next Q1.56 Inst Own67.00% Short Float0.75% Perf Quarter0.30%
Sales71.60B P/S4.34 EPS this Y-3.90% Inst Trans-0.06% Short Ratio2.89 Perf Half Y-7.55%
Book/sh26.64 P/B4.28 EPS next Y6.02% ROA11.60% Target Price125.05 Perf Year22.34%
Cash/sh14.86 P/C7.68 EPS next 5Y6.53% ROE22.10% 52W Range91.69 - 124.38 Perf YTD-0.92%
Dividend3.20 P/FCF60.05 EPS past 5Y2.80% ROI14.70% 52W High-8.22% Beta0.75
Dividend %2.80% Quick Ratio2.40 Sales past 5Y2.60% Gross Margin69.60% 52W Low24.50% ATR1.19
Employees127100 Current Ratio2.70 Sales Q/Q4.20% Oper. Margin26.00% RSI (14)40.83 Volatility0.80% 0.98%
OptionableYes Debt/Eq0.37 EPS Q/Q28.20% Profit Margin22.30% Rel Volume1.07 Prev Close114.20
ShortableYes LT Debt/Eq0.32 EarningsJan 24 BMO Payout53.40% Avg Volume7.03M Price114.15
Recom2.50 SMA20-1.12% SMA50-0.61% SMA200-1.36% Volume7,499,223 Change-0.04%
Oct-19-16Reiterated UBS Buy $137 → $144
Jul-21-16Reiterated Deutsche Bank Hold $125 → $142
Jul-20-16Reiterated UBS Buy $126 → $137
Jul-20-16Reiterated RBC Capital Mkts Outperform $125 → $133
May-20-16Initiated Standpoint Research Sell $94
Apr-20-16Reiterated RBC Capital Mkts Outperform $122 → $125
Apr-20-16Reiterated Piper Jaffray Neutral $105 → $106
Apr-15-16Reiterated RBC Capital Mkts Outperform $114 → $122
Mar-14-16Upgrade Goldman Sell → Neutral
Dec-01-15Upgrade Barclays Equal Weight → Overweight $101 → $115
Oct-05-15Resumed Piper Jaffray Neutral $105
May-21-15Reiterated Deutsche Bank Hold $106 → $110
Dec-08-14Reiterated RBC Capital Mkts Outperform $110 → $114
Jul-16-14Reiterated Deutsche Bank Hold $102 → $107
Apr-17-14Reiterated Argus Buy $104 → $116
Apr-16-14Reiterated RBC Capital Mkts Outperform $104 → $106
Jan-10-14Downgrade Barclays Overweight → Equal Weight $99
Jan-07-14Upgrade RBC Capital Mkts Sector Perform → Outperform $88 → $104
Dec-16-13Reiterated Deutsche Bank Hold $93 → $95
Jul-18-13Reiterated Argus Buy $96 → $104
Jan-22-17 03:24PM  Better Buy: GlaxoSmithKline PLC vs. Johnson & Johnson at Motley Fool
10:35AM  What to Expect From the Dow Stocks Reporting Next Week
Jan-21-17 02:02PM  5 Drugs That Are Way Cheaper in Canada at Motley Fool
08:35AM  Earnings Preview: What To Expect From Johnson & Johnson On Tuesday at Forbes
Jan-20-17 08:45PM  Can Johnson & Johnson Sustain Its Growth in 2017? at Motley Fool
12:08PM  Top 10 Multinational Corporations in the US at Insider Monkey
10:36AM  What Does Johnson & Johnson Predict for Its Medical Devices Segment?
10:27AM  Best Dividend Stocks for 2017 at Motley Fool
10:27AM  Johnson & Johnson : JNJ-US: Dividend Analysis : November 22nd, 2016 (record date) : By the numbers : January 20, 2017
09:24AM  [$$] US stocks outlook: cloudy with meatloaves at Financial Times
09:07AM  How Did JNJs Pharmaceuticals Segment Perform in 4Q16?
08:39AM  Johnson & Johnson's Ethicon Endo-Surgery to acquire medical device maker Megadyne Medical Products at MarketWatch
08:30AM  Ethicon Announces Acquisition of Megadyne Medical Products, Inc. PR Newswire
08:02AM  Are You Undervaluing These 3 Biopharmas' Pipelines? at Motley Fool
07:38AM  Why Johnson & Johnsons 4Q16 Revenues Could Grow
02:00AM  Sanofi's M&A misses frustrate some investors in drugmaker Reuters
Jan-19-17 10:48PM  The Latest: Karen Pence hopes to keep advocating art therapy
04:41PM  Gilead, Merck, Alexion 2017 Views Hazy; Biogen May Surge: Analyst
04:39PM  What to Expect from Johnson & Johnsons 4Q16 Earnings
04:01PM  Low-Yield Dividend Stocks Belong in Your Portfolio
01:27PM  The Best Dividend Stocks for Long-Term Investors at Motley Fool
01:06PM  Merck, Biogen, Lilly Top 2016 Drug Approvals Despite FDA Slump
11:11AM  A Green Light on Bayer
09:12AM  How Johnson & Johnson Beat Every Other Big Pharma Stock in 2016 at Motley Fool
06:00AM  Deal of the Week : J&J Nears Actelion Takeover Despite Twists and Turns at Bloomberg
Jan-18-17 07:38PM  Ten Dividend Stocks To Own Forever And Get Rich Slowly at Forbes
05:01PM  5 Most Important Drugs to Johnson & Johnson in 2017 at Motley Fool
12:59PM  EU mergers and takeovers (Jan 18) Reuters
08:40AM  What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?
05:40AM  [$$] Pfizer warns of 'big challenge' ahead from strong dollar at Financial Times
Jan-17-17 03:15PM  Does Luxottica Now Have A Monopoly On The Eyeglass Space?
10:45AM  Does Johnson & Johnson Pass the Buffett Test? at Motley Fool
10:20AM  Boring stocks get more exciting as Trump rally fades at MarketWatch
09:59AM  Why Bristol-Myers Squibb May Be a Merger Target Soon
08:40AM  Quality Dividends On The Cheap With This ETF
Jan-16-17 02:13PM  3 Bold Bets on the Future of Healthcare at Motley Fool
10:37AM  How Is Novartiss Revenue Trending?
08:21AM  3 Stocks to Buy During a Stock Market Crash at Motley Fool
07:35AM  The Word on the Street: What Analysts Are Recommending for JNJ
07:27AM  Is Donald Trump Big Pharma's Worst Nightmare? at Motley Fool
Jan-14-17 12:01AM  [$$] Dividend-Hike Heroes at Barrons.com
Jan-13-17 04:39PM  Will This Be a Genius or Foolish Move for Johnson & Johnson? at Motley Fool
11:36AM  Intuitive Surgicals 4Q16 Preliminary Results: Higher Revenues?
10:38AM  Behind Johnson & Johnsons Recent Stock Performance
10:06AM  Here's Why Johnson & Johnson Shares Are Poised for a Rally at TheStreet
09:08AM  Could Johnson & Johnson Rip Higher by 20%?
09:07AM  Inside Johnson & Johnsons Latest Dividend Payment
07:36AM  Understanding Johnson & Johnsons Medical Device Business Lawsuit Troubles
Jan-12-17 02:45PM  Pharma company executives debate drug pricing increases
12:12PM  Mylan CEO Heather Bresch says caps on drug price increases wont work at MarketWatch
10:37AM  Johnson & Johnsons Expandable Cage Acquisition to Accelerate the Spine Division
09:10AM  7 Reasons AbbVie's Stock Could Soar in 2017 at Motley Fool
09:08AM  Johnson & Johnsons Diabetes Launch to Accelerate the Medical Device Business
07:58AM  Johnson & Johnson breached its 50 day moving average in a Bearish Manner : JNJ-US : January 12, 2017
07:49AM  Early movers: AAPL, DAL, DIS, AMZN, GS, JNJ, BA, TM & more at CNBC
07:37AM  Inside the Latest Capability Advancement in Johnson & Johnsons Orthopedics
07:35AM  Trump criticism leads to falling stock prices at these Tampa employers at bizjournals.com
Jan-11-17 09:17PM  [$$] Drug stocks tumble as Trump singles out pharma companies at Financial Times
07:32PM  Orthocell Announces Collaboration with Johnson & Johnson Innovation Business Wire
05:53PM  How a Big Pharma player learns, teaches about gender bias BioFlash podcast at bizjournals.com
05:23PM  JNJ, Actelion Reportedly Move Closer to a Deal
05:01PM  Is Trump the biggest risk to his own rally?
04:16PM  Correction: Drug Prices-Johnson & Johnson story
04:04PM  J&J, Actelion Said to Reach Tentative Agreement on Price at Bloomberg
03:14PM  What pharma investors ought to do after Donald Trump fires a salvo at MarketWatch
02:23PM  Johnson & Johnson (JNJ) Gets $17 Million From NYC For JLABS Incubator at Insider Monkey
08:27AM  Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults
Jan-10-17 07:15PM  Trump Tax Policies Could Make J&J a Bigger Threat in 2017
05:55PM  New England Venture Capital Association adds new board members at bizjournals.com
05:55PM  Johnson & Johnson CEO's Fireside Chat: 5 Things You Need to Know at Motley Fool
01:40PM  Will This Cure What Ails Valeant Pharmaceuticals? at Motley Fool
01:40PM  1 Perfect Stock to Invest in the Pharmaceutical Industry at Motley Fool
12:13PM  Johnson & Johnson Could Benefit From Tax Reform at TheStreet
10:41AM  Top Biotech Resolutions for 2017 at Motley Fool
09:39AM  Top Stocks to Buy Now That the 21st Century Cures Act Has Passed at Motley Fool
09:00AM  Dr. Paul Janssen Award for Biomedical Research Issues 2017 Call for Nominations PR Newswire
08:02AM  Johnson & Johnson Stock Split: Coming in 2017? at Motley Fool
07:51AM  Early movers: YHOO, VRX, CUDA, UNH, BABA, JNJ, GS & more at CNBC
02:08AM  Japan's Takeda ready for fresh acquisitions after $5.2 bln Ariad deal
01:02AM  Johnson & Johnson to Report Average Increases in List Prices for U.S. Drugs at The Wall Street Journal
12:00AM  Johnson & Johnson to Report Average U.S. Price Increases at The Wall Street Journal
Jan-09-17 06:28PM  The Best DRIP Stocks: 15 No-Fee Dividend Aristocrats
03:22PM  J&J CEO: Company spoke with Trump team about health-care system at CNBC
02:33PM  Johnson & Johnson CEO Gorsky Discusses What Drove the Stock in 2016
01:36PM  Sanofi Sees No Opening to Actelion Talks After J&J Re-Entry at Bloomberg
01:18PM  Cameron Dallas: Internet Sensation Turned Fashion Star at MarketWatch
01:15PM  J&J CEO: Pleased with performance, but far from satisfied
12:41PM  The 2 Critical Cogs That Pushed Johnson & Johnson 12% Higher in 2016 at Motley Fool
11:40AM  WellCare snags an HR exec from Johnson & Johnson at bizjournals.com
10:08AM  The Charts Show These Two Blue Chips Are Poised for a Big Breakout
06:55AM  Will Johnson & Johnson Shock Investors with a Spin-off in 2017? at Motley Fool
Jan-07-17 11:43AM  3 Dividend Aristocrats to Buy in January at Motley Fool
Jan-06-17 03:32PM  Dow 20K winners & losers since Election Day
10:55AM  7 Dividend Stocks to Put on Your Shopping List at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, Barclays, Procter & Gamble, Kellogg and Medtronic
08:17AM  Bristol-Myers, J&J Ink Immunotherapy Research Collaboration
07:24AM  Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View
06:45AM  The Next 10 Companies Trump Will Trash on Twitter
03:25AM  A Teens Life Hangs in Balance as India Wages Superbug War
02:01AM  J&J, Actelion approach Swiss takeover board over deal structure: paper Reuters
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates through three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women's health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages under the BAND-AID brand name and first aid products under the NEOSPORIN brand name. This segment also provides over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases and vaccines, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular disease; sterilization and disinfection products to reduce surgical infection; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company offers its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use, as well as for use in the professional fields by physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PRINCE CHARLESDirectorOct 21Buy114.1187599,84626,520Oct 25 01:52 PM
JOHNSON & JOHNSON10% OwnerAug 16Buy12.00583,3336,999,9962,449,183Aug 18 05:11 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Option Exercise65.6241,1462,700,001157,819Jul 28 04:34 PM
Caruso Dominic JExec VP, Finance; CFOJul 26Sale125.0141,1465,143,810116,673Jul 28 04:34 PM
Kapusta Ronald AController, CAOJul 22Sale125.012,935366,89625,725Jul 25 03:18 PM
Kapusta Ronald AController, CAOJul 21Option Exercise58.332,935171,19928,660Jul 25 03:18 PM
Kapusta Ronald AController, CAOJun 07Option Exercise58.333,000174,99028,725Jun 09 04:11 PM
Pruden Gary JExec VP, WW Chair, Med DevicesJun 07Sale116.039,7351,129,55243,630Jun 09 04:12 PM
Kapusta Ronald AController, CAOJun 07Sale115.793,000347,38125,725Jun 09 04:11 PM
Kapusta Ronald AController, CAOMay 10Option Exercise58.333,957230,81229,682May 12 05:09 PM
Kapusta Ronald AController, CAOMay 10Sale114.773,957454,15725,725May 12 05:09 PM
Caruso Dominic JVP, Finance; CFOFeb 08Option Exercise0.0029,0050125,466Feb 10 06:02 PM
Gorsky AlexChairman, CEOFeb 08Option Exercise0.0067,9330197,441Feb 10 06:02 PM
PETERSON SANDRA EGroup Worldwide ChairmanFeb 08Option Exercise0.007,633037,943Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 08Option Exercise0.0018,777056,512Feb 10 06:03 PM
Ullmann Michael HVP, General CounselFeb 08Option Exercise0.0016,697098,071Feb 10 06:03 PM
Stoffels PaulusChief Scientific OfficerFeb 08Option Exercise0.0028,2420131,104Feb 10 06:03 PM
Kapusta Ronald AController, CAOFeb 08Option Exercise0.002,598026,023Feb 10 06:03 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Option Exercise72.54144,56810,486,963182,303Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 03Sale104.12144,56815,052,42037,735Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Option Exercise72.546,817494,50544,552Feb 04 06:04 PM
Fasolo PeterVP, Global Human ResourcesFeb 02Sale104.096,817709,58837,735Feb 04 06:04 PM